FDA Panel Examines Novo’s Tresiba and Ryzodeg

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to review Novo Nordisk’s insulin Degludec (Tresiba) and DegludecPlus (Ryzodeg, insulin Degludec/insulin aspart) for type I and type II diabetes on Nov. 8.

Read more>>

Bloomberg BRIEF Newsletters